Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.

Autor:	Eyre TA; Oxford Cancer and Hematology Centre, Oxford University NHS Foundation Trust, Oxford, UK., Hess LM; Eli Lilly and Company, Indianapolis, IN, USA., Sugihara T; Syneos Health, Inc, Morrisville, NC, USA., He D; Syneos Health, Inc, Morrisville, NC, USA., Khanal M; Eli Lilly and Company, Indianapolis, IN, USA., Pagel JM; Loxo@Lilly, Indianapolis, IN, USA., Walgren RA; Loxo@Lilly, Indianapolis, IN, USA., B Abada P; Loxo@Lilly, Indianapolis, IN, USA., Konig H; Loxo@Lilly, Indianapolis, IN, USA., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mato A; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	Leukemia & lymphoma [Leuk Lymphoma] 2023 May; Vol. 64 (5), pp. 1005-1016. Date of Electronic Publication: 2023 Mar 29.
DOI:	10.1080/10428194.2023.2190436
Abstrakt:	This retrospective study using the nationwide de-identified Flatiron Health electronic health record-derived database was designed to evaluate clinical outcomes among patients with chronic lymphocytic leukemia (CLL) who previously received both a covalent Bruton's tyrosine kinase inhibitor (cBTKi) and B-cell lymphoma 2 inhibitor (BCL2i) in a real-world setting. Outcomes for the immediate next line of therapy following the latter of the cBTKi or BCL2i treatment included: real-world response rate of 34.4% (using methods most consistent with clinical trials); median duration of real-world response of 13.3 months; and median real-world progression-free survival of 9.2 months. Median overall survival was 25.5 months from the start of the immediate next line of therapy. There remains a need for more effective therapies after cBTKi and BCL2i therapy for patients with CLL.
Databáze:	MEDLINE
Externí odkaz: